This leads to the conclusion that SAA2 and SAA1β isoforms can serve as RA biomarkers before the symptoms onset (along with RF and anti-CCP), while the SAA1α/SAA1β ratio is useful for evaluating disease severity and response to treatment. This evidence concerns the gene SAA2 and rheumatoid arthritis.